24 jul: Bobler fra dybet fik hammerslag på rekordpriser ved nyligt afhold..
01 aug: Mercedes CLS Shooting Brake på vej til Danmark
26-07-2012 07:54:00

Sanofi Second-Quarter Net Profit up 16% Boosted by Tax Effect

Relateret indhold

By Noemie Bisserbe

PARIS--France's top drug maker Sanofi SA (SNY, SAN.FR) said Thursday it expected its earnings to fall this year, dented by the loss of patents on some of its blockbuster drugs, even as it posted a firm increase in second-quarter net profit, boosted by a tax effect.

The Paris-based pharmaceutical major said net profit attributable to shareholders rose 16% to 1.17 billion euros (US$1.4 billion) in the quarter ended June 30, from EUR1.01 billion a year earlier.

Business net income--the term it uses for adjusted income excluding items such as impacts associated with acquisitions and divestments--was, however, down 9.6% to EUR1.94 billion, hit by the loss of its patents on top-selling drugs--blood thinner Plavix and Avapro, a drug used to treat high blood pressure.

Analysts had forecast a second-quarter business net profit of EUR1.88 billion.

Sanofi's woes underscore drug makers' growing difficulty in keeping their heads above water as they swim from one blockbuster drug to another. On Wednesday, GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Co. (BMY) and Eli Lilly & Co. (LLY) reported sharp drops in second-quarter net profit, hit by a wave of patent expirations for top-selling drugs.

Sanofi maintained its full-year guidance for a 12% to 15% decline in business earnings per share in 2012, assuming no major changes in exchange rates.

Analysts, however, expect Sanofi's earnings to rebound from 2013, as the group strives to rely less on innovative drug sales.

Sanofi, which is struggling with patent expirations, has been extending its pharmaceutical business to growth areas such as emerging markets, vaccines, diabetes solutions, consumer health care, innovative products and animal health, in a bid to become less dependent on patented medicines.

Net sales rose 6.2% to EUR8.87 billion, with revenue at the flagship pharmaceutical division increasing 5.1% to EUR7.5 billion.

Write to Noemie Bisserbe at noemie.bisserbe@dowjones.com

Order free Annual Report for Sanofi

Visit http://djnweurope.ar.wilink.com/?ticker=US80105N1054 or call +44 (0)208 391 6028

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 26, 2012 01:54 ET (05:54 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Nye digitale betalingsløsninger bryder frem

25-09-2017 08:45:00
Sponsoreret indhold:Af Jens Damgaard, Country Manager, Visa DenmarkEfter 20 år, hvor danskerne har taget imod ganske mange nye løsninger indenfor elektroniske/digitale betalinger, går udviklingen nu endnu hurtigere, og det gør Danmark til et af de mest avancerede betalingsmarkeder i Europa. Avanceret, fordi danskerne er parat til at bruge næsten enhver tænkelig mobil enhed til at betale med.Buti..

Novo: Fiasp godkendt i USA

29-09-2017 16:20:48
De amerikanske sundhedsmyndigheder, FDA, har godkendt Fiasp (hurtigtvirkende insulin aspart), en ny hurtigtvirkende måltidsinsulin, til behandling af voksne med diabetes.Det oplyser Novo Nordisk.FDA's beslutning kommer, efter at kliniske studier har dokumenteret, at Fiasp giver fordele for mennesker, der har behov for en forbedret generel blodsukkerregulering.- Vi er meget glade for, at Fiasp nu o..

Atlantic Petroleum: Direktør fratræder 1. december

29-09-2017 14:02:37
Topchefen for Atlantic Petroleum, der er noteret i Norge og København, direktør Ben Arabo, har opsagt sit job for at tiltræde et andet job på Færøerne.Det oplyser selskabet.Han vil dog blive hos Atlantic Petroleum til 1. december./ritzau/FINANSClaus Mikkelsen +45 33 30 03 35 Ritzau Finans, E-mail: finans@ritzau.dk , www.ritzaufinans.dk

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Novo og Genmab i fokus på afventende dag
2
Aktier/åbning: Novo stiger op til ekspertdom - Genmab fortsætter ned
3
Novo: Mulig milliardsællerts skæbne er i eksperternes hænder - GENT
4
Aktier/middag: Tunge Novo trækker C20 ud i overhalingsbanen
5
ISS får sin største kontrakt nogensinde på 33 milliarder over ti år

Relaterede aktiekurser

Sanofi 84,51 0,7% Stigning i aktiekurs
Sanofi American Deposita.. 49,60 0,0% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. oktober 2017 22:00:01
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171017.1 - EUROWEB5 - 2017-10-18 22:00:01 - 2017-10-18 22:00:01 - 1 - Website: OKAY